Weekly Recap | Summit Therapeutics -0.31%, most brokers rate it buyWeekly Review·Sep 12 at 06:49 AMSMMT-5.54%
Weekly Recap | Summit Therapeutics +28.22%, most brokers rate it buyWeekly Review·Sep 5 at 08:06 AMSMMT-5.54%
Weekly Recap | Summit Therapeutics +4.33%, Phase III data beats ImfinziWeekly Review·Aug 29 at 06:29 AMSMMT-5.54%
